The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The chronic hepatitis B market has shown steady growth in recent years and continues to expand. In 2023, the market size was valued at $3.62 billion and is projected to reach $3.77 billion in 2024, growing at a compound annual growth rate (CAGR) of 4.2%.

• Key growth drivers:Advances in antiviral therapy, improved diagnostic techniques, rising prevalence of HIV, and increased awareness and government initiatives.

Growth Forecast for the Chronic Hepatitis B Market

The chronic hepatitis B market is expected to grow significantly over the next few years. By 2028, the market is projected to reach $4.47 billion, growing at a CAGR of 4.3%.

• Factors driving growth:Expansion in emerging markets, increased government funding, improved diagnostics and screening, rising healthcare expenditure, and growing strategic collaborations and partnerships.

Drivers of Growth: High Prevalence of Hepatitis B Infection

The high prevalence of chronic hepatitis B infection is a major factor driving the market’s growth. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination.

• Contributing factors: Low vaccination coverage in low- and middle-income countries leading to higher transmission rates and increasing demand for diagnostic tests and treatments.
• Example: In 2021, the European Centre for Disease Prevention and Control reported 16,187 cases of hepatitis B in 30 Eastern European Member States, highlighting the ongoing need for effective treatments and prevention strategies.

View More On The Chronic Hepatitis B Market Report 2024 – https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Major Players in the Chronic Hepatitis B Market

Several key players dominate the global chronic hepatitis B market, contributing to its growth through innovations and strategic partnerships.

• Leading companies:Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., and more.

Market Trends: Strategic Partnerships and Collaborations

Strategic partnerships and collaborations are a major trend in the chronic hepatitis B market, as companies seek to enhance their technological capabilities and expand their market reach.

• Notable partnership:In January 2021, Gilead Sciences Inc. partnered with VIR Biotechnology to explore novel combination therapies aimed at achieving a functional cure for chronic hepatitis B virus (HBV). This collaboration reflects the industry’s focus on developing curative therapies and improving patient outcomes.

Mergers and Acquisitions: GSK’s Strategic Move

Mergers and acquisitions are also shaping the chronic hepatitis B market, with companies seeking to expand their portfolios and strengthen their positions.

• Example:In November 2023, GSK plc acquired exclusive rights to Janssen Pharmaceuticals’ hepatitis B therapy for $1 billion, aiming to enhance its chronic hepatitis B treatment offerings and drive market growth.

Market Segmentation

The chronic hepatitis B market is segmented by drug class, gender, and distribution channel.

• By Drug Class:Antivirals, Immune Modulators
• By Gender:Male, Female
• By Distribution Channel:Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers

Regional Insights

North America was the largest region in the chronic hepatitis B market in 2023, driven by advanced healthcare infrastructure, high awareness levels, and significant government support.

• Regional growth drivers:Increased healthcare expenditure, robust pharmaceutical industry presence, and strong focus on research and development in the region.

Request A Sample Of The Global Chronic Hepatitis B Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=17112&type=smp